23/04/2019 23:28:45

AVEO FRIDAY DEADLINE ALERT: Rosen Law Firm Reminds AVEO Pharmaceuticals, Inc. Investors of Important April 26th Deadline in Securities Class Action Lawsuit – AVEO

NEW YORK, April 23, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) from August 4, 2016 through January 31, 2019, inclusive (the “Class Period”) of the important April 26, 2019 lead plaintiff deadline in the securities class action lawsuit filed against the company. The lawsuit seeks to recover damages for AVEO investors under the federal securities laws.

To join the AVEO class action, go to https://www.rosenlegal.com/cases-register-1519.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the TIVO-3 trial was inadequately designed to address the overall survival concerns regarding AVEO’s lead candidate drug, tivozanib, from the TIVO-1 trial presented back in the June 2013; (2) tivozanib had insufficient survival data to obtain U.S. Food and Drug Administration (“FDA”) approval following its initial rejection by the FDA in 2013; (3) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (4) as a result, AVEO’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 26, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to https://www.rosenlegal.com/cases-register-1519.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors.

-------------------------------

Contact Information:

      Laurence Rosen, Esq.

      Phillip Kim, Esq.

      The Rosen Law Firm, P.A.

      275 Madison Avenue, 34th Floor

      New York, NY  10016

      Tel: (212) 686-1060

      Toll Free: (866) 767-3653

      Fax: (212) 202-3827

      lrosen@rosenlegal.com

      pkim@rosenlegal.com

      cases@rosenlegal.com

      www.rosenlegal.com

Related content
26 Apr - 
APRIL 26 DEADLINE: Bragar Eagel & Squire, P.C. Announce..
25 Apr - 
CLASS ACTION UPDATE for CORT, AVEO, NIO and CRBP: Levi ..
25 Apr - 
FRIDAY DEADLINE: The Schall Law Firm Announces the Fili..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
CUMULUS MEDIA Announces Pricing of $525 Million Senior Secured Term Loan B
2
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Intersect ENT, Floor & Décor, RCI Hospitality, and EQT Corporation and Encourages Investors to Contact the Firm
3
Uberall & Trustpilot Unveil Integration to Make it Easier for Businesses to Manage Customer Reviews Across Multiple Locations
4
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Molson Coors, Maxar Technologies, Weight Watchers, and Mueller Water and Encourages Investors to Contact the Firm
5
AGF’s Long-term Investment in the U.K. Delivers Strategic Value to Its Shareholders

Related stock quotes

Aveo Pharmaceuticals Inc 0.9578 -3.3% Stock price decreasing

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 September 2019 00:54:00
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190829.2 - EUROWEB2 - 2019-09-20 01:54:00 - 2019-09-20 00:54:00 - 1000 - Website: OKAY